Zohydro Gains Massachusetts Approval: Minor Catalyst

In March 2014, Zohydro was blocked by regulators in the state of Massachusetts.However on August 4, 2014, Zohydro was included back onto the MassHealth drug list, with “prior authorization.” And according to Masshealth, “The updates to the List are effective immediately, unless otherwise specified. For medications that have new PA requirements.”Zygonex (NASDAQ: ZGNX), moved higher by 11.1 percent in Tuesdays pre-market trading session. However the optimism faded on Tuesday's trading session. Difei Yang from R.F. Lafferty & Co stated, “The impact from Massachusetts approval of Zohydro won't add much in terms of incremental revenue for Zygonex. The Massachusetts approval was a minor catalyst.” Zogenix most recently traded at $1.34, and was up by .34 percent.